RETROTOPE
Retrotope creates a new category of drug platform to preserve and restore mitochondrial health in degenerative diseases. It is a privately held company focused on the development of ways of controlling metabolic processes associated with oxidative stress conditions. Retrotope uses isotope effect to slow down damaging pathways. The company has several discovery and development programs that involve major classes of biopolymers, with the major focus on neurological diseases such as Friedreich's ataxia. It was founded in 2006 and is located in Los Altos Hills, California.
RETROTOPE
Industry:
Biotechnology Health Care Medical
Founded:
2006-01-01
Address:
Los Altos Hills, California, United States
Country:
United States
Website Url:
http://www.retrotope.com
Total Employee:
11+
Status:
Active
Contact:
(650) 917-9256
Total Funding:
82.73 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Current Advisors List
Board_member
2019-01-01
Board_observer
2020-12-01
Current Employees Featured
Mikhail Shchepinov Founder and CSO @ Retrotope
Founder and CSO
Charles Cantor Co-Founder and Executive Director @ Retrotope
Co-Founder and Executive Director
Peter Milner Chief Medical Officer @ Retrotope
Chief Medical Officer
2015-03-01
Vidhya Gopalakrishnan Chief Development Officer @ Retrotope
Chief Development Officer
2020-09-01
Founder
Investors List
MEHTA FAMILY PARTNERS
MEHTA FAMILY PARTNERS investment in Series C - Retrotope
Timur Artemev
Timur Artemev investment in Series C - Retrotope
Morningside Venture Investments
Morningside Venture Investments investment in Series C - Retrotope
Harry Saal
Harry Saal investment in Series B - Retrotope
North Texas Angel Network
North Texas Angel Network investment in Series B - Retrotope
SDL Ventures
SDL Ventures investment in Series B - Retrotope
Life Science Angels
Life Science Angels investment in Series B - Retrotope
Green Park & Golf Ventures
Green Park & Golf Ventures investment in Series B - Retrotope
Official Site Inspections
http://www.retrotope.com Semrush global rank: 3.57 M Semrush visits lastest month: 4.06 K
- Host name: ip-173-201-180-24.ip.secureserver.net
- IP address: 173.201.180.24
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Retrotope"
Home Retrotope Inc. (650) 437-0700 - Reinforcing the molecules …
At Retrotope, we are pioneering the development of first-in-class therapies for devastating degenerative diseases - ranging from orphan neurodegenerative indications to large market …See details»
About - Retrotope
By leveraging our unique insight into LPO and our proprietary technology platform, we have created a pipeline of first-in-class therapeutic candidates for the treatment of a range of …See details»
Company Overview - Retrotope
Retrotope is a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for degenerative diseases ranging from orphan neurodegenerative indications …See details»
Retrotope - Wikipedia
Retrotope, Inc. is a drug development company advancing the idea that polyunsaturated fatty acids (PUFA) drugs fortified with heavy isotopes (reinforced lipids) protect living cells by making bonds within the delicate molecules inside and around cells harder to break. This makes the cells less prone to damage caused by reactive oxygen species (ROS), one of the princip…See details»
Retrotope - Crunchbase Company Profile & Funding
Retrotope creates a new category of drug platform to preserve and restore mitochondrial health in degenerative diseases. It is a privately held company focused on the development of ways of controlling metabolic processes …See details»
Retrotope - mitoworld.org
Retrotope is developing a new class of drugs designed to combat the disease and cellular degeneration that results from lipid peroxidation (LPO). By leveraging our unique insight into …See details»
Retrotope Company Profile 2024: Valuation, Funding
Developer of pharmaceutical therapeutics designed to treat degenerative diseases.See details»
Retrotope Announces Initiation of Phase 2 Study of RT001 in …
Mar 17, 2021 · RT001 is a clinical-stage isotopically stabilized, synthetic linoleic acid (LA) discovered and developed with Retrotope’s novel platform technology. This platform is …See details»
Anil Kumar - President & Director at Retrotope - The Org
Anil Kumar is an experienced business advisor to CEO’s, senior management, NGO’s, foundations, owners and boards of businesses. In addition to his role with Retrotope, he also …See details»
Patient Resources - Retrotope
Before a new therapy can be made available to the public, regulated clinical trials involving patient volunteers must be conducted to evaluate the safety and effectiveness of the therapy. Our …See details»
Retrotope looks to fund neurodegenerative disease …
Aug 27, 2021 · California-based Retrotope’s lead asset, RT001, is a synthetic linoleic acid that fights cellular degeneration and oxidative stress caused by lipid peroxidation, chief medical officer Peter Milner explained.See details»
Retrotope Announces Completion of Enrollment in Phase 2 Study …
LOS ALTOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for …See details»
Retrotope - Funding, Financials, Valuation & Investors - Crunchbase
Retrotope is a developer of a new category of drug platform to preserve and restore mitochondrial health in degenerative diseases.See details»
A Brief Look at Retrotope – Fight Aging!
Oct 30, 2015 · Mikhail Shchepinov, director of Retrotope, a biotech company based in Los Altos, California, wants eventually to slow down the ageing process. But he is starting with a related …See details»
Retrotope - VentureRadar
Website: http://www.retrotope.com/ Develops clinical-stage biopharmaceutical therapies for degenerative diseases using proprietary drug discovery platform to create novel, disease …See details»
Careers - Retrotope
We have united in our mission to treat patients by fortifying cells against the degenerative cascade of lipid peroxidation. Retrotope is growing! We need talented and curious team …See details»
SSG Advises Retrotope, Inc. in the Sale of Substantially all of its ...
Retrotope, founded in 2006 and based in Los Altos, California, is a clinical stage biotechnology company developing drugs to combat serious and debilitating neurological and retinal …See details»
Videos - Retrotope
Retrotope released new data at the National Organization of Rare Diseases’ Rare Diseases & Orphan Products Breakthrough Summit (NORD Summit) regarding the impact of RT001 on …See details»
An expanded access protocol of RT001 in ... - Wiley Online Library
Lipid peroxidation is thought to play a biologically important role in motor neuron death in amyotrophic lateral sclerosis (ALS). 11,11 Di-deuterated linoleic ethyl ester (RT001) prevents …See details»
News - Retrotope
News of Retrotope's recent rare pediatric disease designation for RT001 in INAD was included in AAO's "Week in Review" roundup of key ophthalmic news. Did you know Retrotope also has a …See details»